PURMX Therapeutics, Inc. (PURMX Therapeutics; Headquarters: Hiroshima, Japan; President: Hidetoshi Tahara; hereafter “the Company”) is pleased to report that it has issued new shares through a third-party allotment to KII No. 3 Impact Investment Limited Liability Partnership. This third-party allotment brings PURMX Therapeutics' cumulative total raised to approximately 1.2 billion yen (7.8 million USD).
Press release_Apr 2024_Series A
.pdf
Download PDF • 317KB